Results 261 to 270 of about 86,105 (313)
Some of the next articles are maybe not open access.
International journal of phytoremediation, 2022
In the present study, sisal–Fe/Zn LDH bio-nanocomposite for efficiently removing rifampin was synthesized using a simple co-precipitation method. SEM, XRD, and FTIR analyses were applied to characterize the prepared composite. In the following, different
M. Negarestani +4 more
semanticscholar +1 more source
In the present study, sisal–Fe/Zn LDH bio-nanocomposite for efficiently removing rifampin was synthesized using a simple co-precipitation method. SEM, XRD, and FTIR analyses were applied to characterize the prepared composite. In the following, different
M. Negarestani +4 more
semanticscholar +1 more source
International Journal of Dermatology, 1993 Rifampicin (Rp) is a semisynthetic derivative of Rifamycin B, an antimicrobial agent produced by Streptomyces mediterranei. Rp is a broad spectrum antimicrobial and inhibits the growth of most Gram-positive bacteria, as well as many Gram-negative microorganisms, such as Escherichia coli, Pseudomonas, indole-positive and indole-negative Proteus, and ...
Nikolai Tsankov, Jivko A. Kamarashev
openaire +2 more sources
Pediatrics In Review, 1996
Rifampin is a semisynthetic derivative of rifamycin B that is active against a wide range of microorganisms and bactericidal for extracellular as well as intracellular pathogens. Most gram-positive and many gram-negative bacteria, as well as mycobactenia, are inhibited by nifampin.
openaire +2 more sources
Rifampin is a semisynthetic derivative of rifamycin B that is active against a wide range of microorganisms and bactericidal for extracellular as well as intracellular pathogens. Most gram-positive and many gram-negative bacteria, as well as mycobactenia, are inhibited by nifampin.
openaire +2 more sources
AAPS Journal, 2019
Cytochrome P450 3A4 (CYP3A4) catalyses the metabolism of > 30% of clinically used small molecule drugs. Induction of CYP3A4 is often associated with clinically important metabolic drug–drug interactions (DDIs).
Asha J. Kapetas +3 more
semanticscholar +1 more source
Cytochrome P450 3A4 (CYP3A4) catalyses the metabolism of > 30% of clinically used small molecule drugs. Induction of CYP3A4 is often associated with clinically important metabolic drug–drug interactions (DDIs).
Asha J. Kapetas +3 more
semanticscholar +1 more source
Annals of Internal Medicine, 1979
Excerpt To the editor: The immunosuppressive effects of rifampin have been well established (1-3). Long-term complications, however, have not yet been reported.
Carol L. Chervenak +2 more
openaire +2 more sources
Excerpt To the editor: The immunosuppressive effects of rifampin have been well established (1-3). Long-term complications, however, have not yet been reported.
Carol L. Chervenak +2 more
openaire +2 more sources
Archives of Internal Medicine, 1984
Rifampin, an antituberculosis agent, is usually administered for nine to 12 months with other antituberculosis drugs or drugs from other classes. A potential for drug interactions often exists because this drug is a potent inducer of drug metabolism. Rifampin causes a proliferation of the smooth endoplasmic reticulum and an increase in the cytochrome P-
Anne M. Baciewicz, Timothy H. Self
openaire +3 more sources
Rifampin, an antituberculosis agent, is usually administered for nine to 12 months with other antituberculosis drugs or drugs from other classes. A potential for drug interactions often exists because this drug is a potent inducer of drug metabolism. Rifampin causes a proliferation of the smooth endoplasmic reticulum and an increase in the cytochrome P-
Anne M. Baciewicz, Timothy H. Self
openaire +3 more sources
JAMA: The Journal of the American Medical Association, 1972
To the Editor.— Rifampin is an effective antituberculous drug recently approved by the Food and Drug Administration for general use. Users are warned that Rifampin has been shown to produce liver dysfunction. There have been fatalities associated with jaundice in patients with liver disease or receiving rifampin concomitantly with other hepatotoxic ...
openaire +2 more sources
To the Editor.— Rifampin is an effective antituberculous drug recently approved by the Food and Drug Administration for general use. Users are warned that Rifampin has been shown to produce liver dysfunction. There have been fatalities associated with jaundice in patients with liver disease or receiving rifampin concomitantly with other hepatotoxic ...
openaire +2 more sources